The emergence of the anti-tumor necrosis factor alpha(anti-TNF-α)therapies has brought lots of benefits to patients with inflammatory bowel disease(IBD).However,controversies exist over whether anti-TNF-α could be used for Crohn's disease(CD)patients with intestinal stricture.Some articles found stricturing CD patients under anti-TNF therapy had a high risk of intestinal obstruction or even perforation while others found that there was no association between anti-TNF-α and intestinal obstruction.The fundamental cause lies in that anti-TNF-α only target at inflammation,but cannot be resistant to intestinal fibrosis or change long term outcome.To avoid and prevent intestinal obstruction or perforation,authors should evaluate the component and type of intestinal stricture cautiously before starting anti-TNF-α therapy.Exploring new specific antifibrotic therapy will be a promising way for all stricturing CD patients.

Colorectal cancer patients with potential resectable liver metastases may benefit from hepatectomy or other local treatment to achieve R 0 resection or no evidence disease after conversion treatment by chemotherapy with or without target therapy. FOLFOX or FOLFIRI combined with cetuximab is appropriate for RAS and BRAF wide type and primary tumor at left-side colon cancer and rectal cancer. It is complex for RAS and BRAF wide type and primary tumor at right-side colon cancer or RAS or BRAF mutated patients. FOLFOXIRI combined with bevacizumab may be the first choice for those patients with young age and good performance score to achieve best conversion chance, while FOLFOX/CapeOx/FOLFIRI combined with bevacizumab could be the second choice. A surgical re-evaluation should be planned every 2 months after initiation of conversion treatment in multi-disciplinary treatment assessment. Once it is demonstrated conversion treatment is successful, surgery should be performed as soon as possible.